Outset Medical, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals

New york, new york--(newsfile corp. - august 6, 2022) - why: rosen law firm, a global investor rights law firm, reminds purchasers of the securities of outset medical, inc. (nasdaq: om) between september 15, 2020 and june 13, 2022, both dates inclusive (the "class period"), of the important september 6, 2022 lead plaintiff deadline.

Bensalem, pa. , aug. 5, 2022 /prnewswire/ -- law offices of howard g.

New york , aug. 5, 2022 /prnewswire/ -- jakubowitz law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of outset medical, inc. (nasdaq: om). to receive updates on the lawsuit, fill out the form: https://claimyourloss.com/securities/outset-medical-loss-submission-form/?id=30564&from=4 this lawsuit is on behalf of all persons or entities who purchased outset medical common stock between september 15, 2020, and june 13, 2022.

New york, new york--(newsfile corp. - august 5, 2022) - the klein law firm announces that a class action complaint has been filed on behalf of shareholders of outset medical, inc. (nasdaq: om) alleging that the company violated federal securities laws.this lawsuit is on behalf of all persons or entities who purchased outset medical common stock between september 15, 2020, and june 13, 2022.lead plaintiff deadline: september 6, 2022no obligation or cost to you.

New york, new york--(newsfile corp. - august 4, 2022) - levi & korsinsky, llp notifies investors in outset medical, inc. ("outset medical" or the "company") (nasdaq: om) of a class action securities lawsuit.the lawsuit on behalf of outset medical investors has been commenced in the the united states district court for the northern district of california.

Outset Medical, Inc. (NASDAQ:OM ) Q2 2022 Earnings Conference Call August 1, 2022 5:00 PM ET Company Participants Jim Mazzola - Vice President Investor Relations Leslie Trigg - Chair & Chief Executive Officer Nabeel Ahmed - Chief Financial Officers Conference Call Participants Travis Steed - Bank of America Josh Jennings - Cowen Suraj Kalia - Oppenheimer Rick Wise - Stifel Phil Coover - Goldman Sachs Drew Ranieri - Morgan Stanley Josh Jennings - Cowen Operator Greetings, and welcome to Outset Medical Q2 2022 Earnings Conference Call. At this time, all participants are in listen-only mode.

A major FDA decision clears the way for Outset to again go after a huge opportunity.

Outset Medical, Inc. (OM) delivered earnings and revenue surprises of -22.22% and 2.39%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

The mean of analysts' price targets for Outset Medical, Inc. (OM) points to a 93.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Medical Info Systems stocks like Omnicell, Inc. (OMCL), Axonics, Inc. (AXNX) and Outset Medical, Inc. (OM) are expected to gain despite pandemic-led disruptions.

The temporary issue could present a great buying opportunity for long-term investors.

Outset Medical Inc (NASDAQ: OM) implemented a shipment hold on the distribution of its Tablo Hemodialysis System for home use pending the FDA review and clearance of a 510(k). The company submitted for changes made since the device's original March 2020 clearance.

These companies have low share prices and high potential.

Outset Medical, Inc. (OM) delivered earnings and revenue surprises of -1.52% and 0.65%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

This company helps keep patients at home with dialysis treatments.